Which processes drive the accumulation of cytotoxic CD8+ T cells in the lungs of COPD patients?

Which processes drive the accumulation of cytotoxic CD8+ T cells in the lungs of COPD patients? - CD8+ T cell and COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31140

Enrollment

Registered

2007-09-06

Start date

2007-08-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease (COPD)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients scheduled for lobectomy for a small peripheral lung lesion or scheduled lung transplantation

Exclusion criteria

Exclusion criteria: - recent (

Design outcomes

Primary

Measure	Time frame
The initial studies using the paired T cells from lung and circulation will focus on three items: 1 Assessment of replicative history 2 Comparison of the clonal composition 3 Determination of the lung T cell transcriptosome From these analyses we will select key markers that are typically expressed by lung residing T cells, to look for differences between participant subgroups, particularly those with and without established COPD. Depending on the characteristics of the specific markers we will use immunohistochemistry on the tissue blocks, FACS analysis of T cells and RT PCR where appropriate. FACS analyses will be performed on total CD8+ T cells and T cells specific for respiratory viruses	—

Measure

Time frame

The initial studies using the paired T cells from lung and circulation will focus on three items: 1 Assessment of replicative history 2 Comparison of the clonal composition 3 Determination of the lung T cell transcriptosome From these analyses we will select key markers that are typically expressed by lung residing T cells, to look for differences between participant subgroups, particularly those with and without established COPD. Depending on the characteristics of the specific markers we will use immunohistochemistry on the tissue blocks, FACS analysis of T cells and RT PCR where appropriate. FACS analyses will be performed on total CD8+ T cells and T cells specific for respiratory viruses

—

Secondary

Measure	Time frame
We aim to obtain BAL CD8+ T cells from the lobe that will be removed during the operation by bronchoscopy and compare these cells to those isolated from the tissue.	—

Countries

Netherlands

Outcome results